PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the pricing of an underwritten public offering of 3,784,000 shares of its common stock, offered at a price to the public of $1.10 per share. The gross proceeds to PURE from this offering are expected to be $4,162,400, before deducting the underwriting discount and other estimated offering expenses payable by PURE. PURE has granted the underwriters a 45-day option to purchase at the public offering price up to an aggregate of 567,600 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about September 17, 2012, subject to customary closing conditions. Aegis Capital Corp. is acting as sole book-running manager for this offering. The offering is being made pursuant to a shelf registration statement that PURE filed with the Securities and Exchange Commission ("SEC") and is effective. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.